The authors are very grateful to Amy Ninetto, PhD, from the Department of Scientific Publications of MD Anderson Cancer Center who edited the manuscript.
The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
This study was supported in part by the NIH through Cancer Center Support Grant P30 CA016672 and by the Young Breast Cancer Survivors Program (104029) from MDACC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or NIH.
CouchFJNathansonKLOffitK. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science2014;343:1466–1470.
BayraktarSGutierrez-BarreraAMLiuD. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat2011;130:145–153.
Wong-BrownMWMeldrumCJCarpenterJE. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat2015;150:71–80.
KwonJSGutierrez-BarreraAMYoungD. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol2010;28:4214–4220.
Gonzalez-AnguloAMTimmsKMLiuS. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res2011;17:1082–1089.
AtchleyDPAlbarracinCTLopezA. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol2008;26:4282–4288.
DalyMBPilarskiRBerryM. NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2018. Accessed October 3 2017. To view the most recent version of these guidelines visit NCCN.org.
RuddyKJRisendalBCGarberJEPartridgeAH. Cancer survivorship care: an opportunity to revisit cancer genetics. J Clin Oncol2015;34:539–541.
SinhaAKPatelJRShenY. Location of receipt of initial treatment and outcomes in long-term breast cancer survivors. PLoS One2017;12:e0170081.
KurianAWGriffithKAHamiltonAS. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA2017;317:531–534.
ChildersCPChildersKKMaggard-GibbonsMMacinkoJ. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol2017;35:3800–3806.
LoboMLopez-TarruellaSLuqueS. Evaluation of breast cancer patients with genetic risk in a university hospital: before and after the implementation of a heredofamilial cancer unit[published online December 15 2017]. J Genet Couns.doi: 10.1007/s10897-017-0187-3
LuKHWoodMEDanielsM. American Society of Clinical Oncology expert statement: collection and use of a cancer family history for oncology providers. J Clin Oncol2014;32:833–840.
ThompsonHSValdimarsdottirHBDuteau-BuckC. Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev2002;11:1579–1585.
SharmaPKlempJRKimlerBF. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat2014;145:707–714.
Schlich-BakkerKJten KroodeHFWarlam-RodenhuisCC. Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer. Genet Med2007;9:766–777.
United States Congress House Committee on Energy and Commerce Subcommittee on Health. The Genetic Information Nondiscrimination Act: Hearing Before the Subcommittee on Health of the Committee on Energy and Commerce House of Representatives One Hundred Tenth Congress first session on H.R. 493. U.S.G.P.O.: for sale by the Supt. of Docs. U.S.G.P.O.; March 8 2007. Washington, DC; 2008.
HudsonKLHolohanMKCollinsFS. Keeping pace with the times—the Genetic Information Nondiscrimination Act of 2008. N Engl J Med2008;358:2661–2663.
WalcottFLDunnBK. Legislation in the genomic era: the Affordable Care Act and genetic testing for cancer risk assessment. Genet Med2015;17:962–964.
KurianAWLiYHamiltonAS. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol2017;35:2232–2239.
JagsiRGriffithKAKurianAW. Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol2015;33:1584–1591.
McCarthyAMBristolMDomchekSM. Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. J Clin Oncol2016;34:2610–2618.